Kit for predetermining treatment effect of iressa on patient with non-small-cell lung cancer by using FAS-1377G/A

Abstract

The invention discloses a kit for predetermining treatment effect of iressa on patient with non-small-cell lung cancer by using FAS-1377G / A. The invention provides special primers which form a primer pair used for amplifying a segment containing FAS-1377G / A, in particular a primer pair formed by a DNA fragment represented by a sequence 1 and a DNA segment represented by a sequence 2. The use of the special primers to help to predict the treatment effect of iressa on non-small-cell lung cancer in the patient has the following advantages: 1, a detection sample may from nucleated cells of any normal or tumor tissue, so almost all patient can obtain a detection sample; 2, FAS-1377G / A belongs to hereditary variation, and the detection result is free from any influence of the sampling time and place; 3, the detection process flow is relative simple and convenient, the equipment requirement is low and the cost is low; and 4, the sensibility is much higher than that of genetic mutation, the detection result is more beneficial to the patient receiving the prediction, and thus, the kit can better meet current sanitary and economic requirements of China.

Description

technical field [0001] The invention relates to a kit for predicting curative effect of gefitinib in patients with non-small cell lung cancer by using FAS-1377G / A. Background technique [0002] Lung cancer is one of the most common malignant tumors with the highest mortality rate, and its morbidity and mortality are still increasing year by year. Among them, non-small cell lung cancer (NSCLC) accounts for more than 80% of the whole lung cancer, and most of the patients are already in advanced stage when they are diagnosed. Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%. [0003] The emergence of targeted therapy drugs has changed the current treatment status of non-small cell lung cancer and significantly improved the survival of patients. Among them, Gefitinib (Gefitinib, ...

AI Technical Summary

Problems solved by technology

Chemotherapy used to be the most important treatment for advanced non-small cell lung cancer, but even with the best chemotherapy regimen, the total effective rate of current treatment is less than 50%, and the 1-year survival rate is only about 40%

However, EGFR gene mutation, as a biomarker for predicting the efficacy of gefitinib, has certain shortcomings: ①The detection of mutation requires tumor tissue, and most lung cancers are already in the advanced stage when they are first diagnosed, and they lose the opportunity to obtain tumor samples through surgery. It is possible for a small number of patients to obtain biopsy specimens, and it is also difficult to perform mutation detection due to the limited detection rate and the limited amount of biopsy specimens. Currently, the proportion of patients who can meet the requirements of mutation detection clinically is less than 20% (about 17% in the ISEL study). %); ②Gene mutations are affected by tumor heterogeneity. Tumor samples obtained from the same patient at different sites or at different stages of the disease may have different mutation detection results, so the detected results may not represent the characteristics of the whole body and the whole tumor ; ③ The process of mutation detection is complicated, the requirements for equipment are high, it is difficult for general laboratories to carry out, and the detection cost is also high, which affects its wide clinical application; ④ As a predictor of curative effect, the sensitivity of mutation is not high (ISEL study 68.8%), and for expensive therapeutic drugs like gefitinib, clinical guidance with high sensitivity is more meaningful

Images